BioSpace News Archive

Long-term use of analgesics such as morphine leads to “tolerance” that reduces drug efficacy. In such cases, dose escalation may be required to achieve the same analgesic effects.

Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in people aged 16 years and older.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that effective December 21, 2023, the Manitoba Pharmacare Program will cover RADICAVA® Oral Suspension for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.1

The network adds five additional research sites, expanding its foothold across North America and its wide range of therapeutic area capabilities

Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant

BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success.

Sanofi announced that its Q4 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”) today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1701 under the U.S. Application No. 16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (ODD) to JR-441, an investigational drug for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA, or Sanfilippo syndrome type A).

Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), in The New England Journal of Medicine.